Literature DB >> 14999225

AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.

A Mohr1, G Henderson, L Dudus, I Herr, T Kuerschner, K-M Debatin, H Weiher, K J Fisher, R M Zwacka.   

Abstract

Gene transfer vectors based on the adeno-associated virus (AAV) are used for various experimental and clinical therapeutic approaches. In the present study, we demonstrate the utility of rAAV as a tumoricidal agent in human colorectal cancer. We constructed an rAAV vector that expresses tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) and used it to transduce human colorectal cancer cells. TRAIL belongs to the TNF superfamily of cytokines that are involved in various immune responses and apoptotic processes. It has been shown to induce cell death specifically in cancer cells. Transduction with AAV.TRAIL gave rise to rapid expression of TRAIL, followed by induction of apoptosis, which could be inhibited by the caspase inhibitor z-VAD.fmk, in several human colon cancer cell lines. The apoptotic mechanism included activation of caspase-3, as well as cytochrome c release from mitochondria. The outgrowth of human colorectal tumors grown in mice was completely blocked by transduction with AAV.TRAIL in vitro, while in vivo transduction significantly inhibited the growth of established tumors. AAV vectors could provide a safe method of gene delivery and offer a novel method of using TRAIL as a therapeutic protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999225     DOI: 10.1038/sj.gt.3302154

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

Review 1.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

Review 2.  Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.

Authors:  Dayananda Kasala; A-Rum Yoon; Jinwoo Hong; Sung Wan Kim; Chae-Ok Yun
Journal:  Nanomedicine (Lond)       Date:  2016-06-27       Impact factor: 5.307

Review 3.  Treatment of human disease by adeno-associated viral gene transfer.

Authors:  Kenneth H Warrington; Roland W Herzog
Journal:  Hum Genet       Date:  2006-04-13       Impact factor: 4.132

4.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 5.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

6.  AAV2-mediated in vivo immune gene therapy of solid tumours.

Authors:  Sara A Collins; Alexandra Buhles; Martina F Scallan; Patrick T Harrison; Deirdre M O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Genet Vaccines Ther       Date:  2010-12-20

7.  Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.

Authors:  Minghong Jiang; Zheng Liu; Yang Xiang; Hong Ma; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  BMC Cancer       Date:  2011-02-03       Impact factor: 4.430

8.  TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.

Authors:  Andrea Mohr; Rui Yu; Ralf M Zwacka
Journal:  BMC Cancer       Date:  2015-07-03       Impact factor: 4.430

9.  Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.

Authors:  Lyse A Norian; Britnie R James; Thomas S Griffith
Journal:  Cancers (Basel)       Date:  2011-02-10       Impact factor: 6.639

10.  Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells.

Authors:  E Ucur; J Mattern; T Wenger; S Okouoyo; A Schroth; K-M Debatin; I Herr
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.